Hosted on MSN12mon
Mankind Pharma block deal: Stock may top Rs 2,500 level in short-term, qualify for MSCI May inclusion, says Nuvamaeye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 4 dedicated R&D facilities backed by more than 600 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback